Endometriosis causes severe chronic pelvic pain and infertility. We have recently reported that niclosamide treatment reduces growth and progression of endometriosis-like lesions and inflammatory signaling (NFKB and STAT3) in a mouse model. In the present study, we examined further inhibitory mechanisms by which niclosamide affects endometriotic lesions using an endometriotic epithelial cell line, 12Z, and macrophages differentiated from a monocytic THP-1 cell line. Niclosamide dose dependently reduced 12Z viability, reduced STAT3 and NFKB activity, and increased both cleaved caspase-3 and cleaved PARP. To model the inflammatory microenvironment in endometriotic lesions, we exposed 12Z cells to macrophage conditioned media (CM). Macrophages were differentiated from THP-1 cells using 12-O-tetradecanoylphorbol-13-acetate as M0, and then M0 macrophages were polarized into M1 or M2 using LPS/IFNγ or IL4/IL13, respectively. Conditioned media from M0, M1, or M2 cultures increased 12Z viability. This effect was blocked by niclosamide, and cell viability returned to that of CM from cells treated with niclosamide alone. To assess proteins targeted by niclosamide in 12Z cells, CM from 12Z cells cultured with M0, M1, or M2 with/without niclosamide were analyzed by cytokine/chemokine protein array kits. Conditioned media from M0, M1, and/or M2 stimulated the secretion of cytokines/chemokines from 12Z cells. Production of most of these secreted cytokines/chemokines in 12Z cells was inhibited by niclosamide. Knockdown of each gene in 12Z cells using siRNA resulted in reduced cell viability. These results indicate that niclosamide can inhibit the inflammatory factors in endometriotic epithelial cells stimulated by macrophages by targeting STAT3 and/or NFKB signaling.
Introduction
Endometriosis is a chronic inflammatory disease characterized by the persistence and growth of endometrial tissue outside the uterine cavity, primarily on the pelvic peritoneum and ovaries [1, 2] .
Although endometriosis is a benign disorder, the majority of affected women experience severe chronic pelvic pain and/or infertility [3, 4] . While surgical removal of lesions and hormonal therapy are current standards, these approaches only temporarily relieve the symptoms, and/or causes various unwanted side effects and a high incidence of relapse [2, [5] [6] [7] [8] [9] [10] [11] . Therefore, it is important to identify therapeutic targets and efficient drugs that are improvements over current treatment options.
Endometriosis is known as an estrogen-dependent inflammatory disease associated with dysregulation of tissue, peritoneal, and peripheral cytokines [1] . Remarkably, increased macrophages, prostaglandins, cytokines, and chemokines have been observed in the peritoneal fluids from endometriosis patients [12] [13] [14] . This milieu of cytokines and growth factors creates a microenvironment that encourages endometrial cell attachment, invasion, and vasculogenesis [12] [13] [14] . Chemokines play a major role in the recruitment of macrophages at the site of endometrial tissue engraftment in the peritoneal cavity, a critical step for neuroangiogenesis in the endometriotic lesions [15, 16] . Thus, the altered inflammatory environment further enhances inflammation, and consequently promotes endometriotic cell survival and growth [15, 17, 18] .
We have recently identified a small molecule, niclosamide, that could be a potential new, effective, fertility-sparing therapy for endometriosis [19] . Niclosamide has been approved by the Food and Drug Administration (FDA) since 1982 and is listed among the World Health Organization's (WHO) essential medicines [20] . Niclosamide has been used in patients for decades as an efficacious, minimally toxic, and affordable drug [21, 22] . Several studies, including ours, have reported that niclosamide disrupts multiple signaling pathways including WNT, mTORC1, STAT3, NFκB, Notch, and Hedgehog signaling in a variety of cancer models (reviewed in [23] , and [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] ). We have recently demonstrated that niclosamide reduces growth and progression of endometriosis-like lesions (ELLs) using a mouse model of endometriosis [19] . Niclosamide inhibits cell proliferation and inflammatory signaling such as STAT3 and RELA (NFKB) activation in ELLs [19] . RNA-sequencing analysis indicated that transcripts associated with inflammatory responses were affected by niclosamide. In addition, treatment of niclosamide for 3 weeks did not cause any obvious adverse effects including weight loss. Furthermore, niclosamide did not disrupt ovarian and uterine functions including estrous cycles, ovulation, pregnancy rates, gestational length, and litter size. Thus, we hypothesized that niclosamide could be an inhibitor of endometriosis progression by blocking inflammatory pathways.
In the present study, we report that niclosamide inhibits macrophage-dependent endometriotic epithelial cell viability and production of cytokines and chemokines in treated cells through STAT3 and/or NFKB signaling.
Materials and methods

Cells
THP-1 human monocyte cell line (TIB-202) was purchased from American Type Culture Collection (ATCC). Immortalized human endometriotic epithelial cells (12Z) were kindly provided by Dr Starzinski-Powitz [38] . THP-1 and 12Z cells were grown in RPMI 1640 with 10% FBS and 200 mM glutamine and penicillin/streptomycin at 37
• C in a humidified 5% CO 2 incubator. All cells were routinely tested for cell proliferation and mycoplasma contamination, and they showed similar growth rate and were negative for mycoplasma throughout the experiments. All experiments were performed in four independent trials with triplicate measurement for each treatment and time point.
Cell viability
Cell viability was performed following our previously described methods [31, 39, 40] 
NFκB reporter assay
NFκB-dependent luciferase reporter activity was examined using Cignal NFκB Pathway Reporter Assay Kit (CCS-013, Qiagen) according to the manufacturer's instructions. Briefly, 12Z cells (5 × 10 4 /well) were seeded in 24-well plates. Cells were transfected with a reporter plasmid encoding pNFκB-Luc and then dosedependently treated with niclosamide and/or 50 ng/ml of TNFα the next day (20 h later). Luciferase activity was measured using Promega's Dual-Luciferase reporter Assay System (E1910, Promega) 24 h post treatment.
Macrophage-epithelial cell interaction studies
THP-1 cells were differentiated into macrophages using supplementation, following established protocols [41, 42] . Briefly, as shown in Figure 1 , THP-1 cells were differentiated into non-polarized macrophages (M0) using 10 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (PMA, Sigma-Aldrich) for 24 h. M0 macrophages were polarized into M1 macrophages by treating with 15 ng/ml of lipopolysaccharide (LPS, Signa-Aldrich) and 50 ng/ml of IFN-γ (Millipore), or M2 macrophages by treating with 25 ng/ml of IL4 (Millipore) and IL13 (Millipore) for 24 h. Then, conditioned media (CM) from M0, M1, or M2 were collected 24 h after the addition of fresh media. 12Z cells were serum-starved for 48 h and then cultured with control (growth media) or 100% CM from M0, M1, or M2 with or without 1 μM niclosamide (Sigma-Aldrich) for 48 h, washed/added fresh media for 24 h, and collected cells for viability and CM from 12Z cells for further analysis.
Conditioned media from 12Z cells (see Figure 1 ) were collected and analyzed using the Proteome Profiler Human XL Cytokine (ARY022B) and Chemokine (ARY017) Array kits (R&D Systems) according to the manufacturer's instructions. Quantitative analysis of spot density was performed using Image J [43] .
Quantitative real-time PCR analysis
Total RNA was isolated from cells, and cDNA was synthesized from total RNA using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher). Relative gene expression was determined by SYBR green (Bio Rad) incorporation using a Bio-Rad CFX as described previously [44] . Primer sequences were determined using NCBI's design tools and are provided in Supplementary Table S1 
Statistical analysis
Data were subjected to one-way ANOVA, and Tukey multiplecomparison post test was used to identify differences between individual means using Prism software (Ver. 5.0, GraphPad). All data met necessary criteria for ANOVA analysis including equal variance as determined by the Bartlett test. All experimental data are presented as mean with standard error of the mean (SEM). Unless otherwise indicated, a P value less than 0.05 was considered to be statistically significant.
Results
Niclosamide inhibits endometriotic epithelial cell functions
Our previous study has demonstrated that niclosamide reduces the size of endometriotic implants with inhibition of cell proliferation and inflammatory signaling using an in vivo mouse model [19] . In this study, to determine whether niclosamide has inhibitory effects on endometriotic epithelial cells, 12Z cells were used to assess cell viability and apoptosis (Figure 2) , and STAT3 and NFKB activation ( Figure 3 ). Niclosamide dose-dependently decreased cell number ( Figure 2A ) and increased cleaved caspase-3 and cleaved PARP ( Figure 2B ). Furthermore, STAT3 activity was observed in 12Z cells and its activity was inhibited by niclosamide treatment ( Figure 3A) . Niclosamide dose-dependently inhibited basal and TNFα-induced NFκB reporter activity in 12Z cells ( Figure 3B ).
Macrophages promote 12Z cell viability and inflammation that are inhibited by niclosamide
Endometriosis is associated with dysregulation of inflammatory factors [1] . Increased macrophages, cytokines, and chemokines have been observed in the peritoneal fluids from endometriosis patients [12] [13] [14] . Thus, we hypothesize that 12Z cells affected by macrophages contribute to the establishment of inflammatory microenvironment and promote endometriotic progression in the peritoneum. Macrophage activation was confirmed by analyzing relative mRNA expression levels of TNF and CD80 for M1, and IL10 for M2 described previously [41, 45] , and are shown in Supplementary Figure S1 . Upon confirmation, we investigated whether the macrophages were able to stimulate 12Z cell viability and inflammatory-related factors. We observed that cell viability was stimulated in 12Z cells primed in media conditioned by M0, M1, or M2 (Figure 4 ). Niclosamide not only inhibited 12Z viability (growth media, Figure 4 ), but also blocked M0, M1, or M2 macrophage-induced 12Z viability (Figure 4) . Furthermore, the macrophage-induced viability returned to that of growth media from cells treated with niclosamide alone. While 1 μM niclosamide did not elicit a significant decrease with complete growth medium (Figure 2A ), we determined that under serum starvation (48 h) conditions, it was the lowest effective dose and was subsequently used for further experiments. Next, we performed protein array to identify proteomic profiles of cytokines and chemokines in 12Z cells that were stimulated by macrophages and targeted by niclosamide (Supplementary Figure  S2 and Figure 5) . ANG, ANGPT2, BDNF, CCL2, CCL5, CCL21, CST3, CXCL10, CXCL12, IL10, IL11, IL22, and MDK identified in 12Z cells were stimulated by CM collected from M1 and/or M2 macrophages. Specifically, CCL5, CCL21, CXCL10, CXCL12, IL22, and MDK were stimulated by both M1 and M2 CM, but ANG, ANGPT2, CCL2, CST3, IL10, and IL11 were only stimulated by M2 CM. We also observed decreased levels of BDNF by M1 CM. Niclosamide inhibited increased secretion of ANG, ANGPT2, BDNF, CCL2, CCL5, CCL21, CST3, CXCL10, CXCL12, IL10, IL11, IL22, and MDK that are stimulated by M1 and/or M2 CM. However, CCL5 and CXCL12 stimulated by M1 CM were not affected by niclosamide.
Downregulation of inflammatory factors in 12Z cells inhibits cell viability
The cytokines and chemokines, which were stimulated in 12Z cells cultured with macrophage CM and subsequently inhibited by niclosamide, represent the best candidate factors that are responsible for niclosamide's beneficial effect in endometriosis. Therefore, we examined whether silencing of these selected cytokines and chemokines could reduce viability in 12Z cells. BDNF, CCL5, CST3, CXCL12, or MDK was knocked down in 12Z cells using validated commercially available siRNAs and AllStars Negative Control (Supplementary Figure S3 ). Reduction of CCL5, CST3, CXCL12, or MDK inhibited viability in 12Z cells, whereas BDNF reduction in 12Z cells did not significantly affect cell viability ( Figure 6A ). In order to determine whether these cytokines and/or chemokines regulate STAT3 activation, the phosphorylation of STAT3 was assessed by western blot analysis. No significant change in STAT3 activation was observed by the reduction of cytokines or chemokines, suggesting that STAT3 activation is upstream of these factors (Figure 6B ), or that combinations of factors must be knocked down simultaneously to recapitulate niclosamide-dependent reduction of STAT3.
Discussion
Previously, we have demonstrated that a nonhormonal and FDAapproved small molecule, niclosamide, inhibits growth and progression of ELLs using an established mouse model [19] . In that study, our results further suggested that niclosamide targets inflammatory mechanisms such as STAT3 and NFKB signaling to reduce ELLs [19] . Comparable to the in vivo findings, the present study showed that niclosamide effectively reduced cell viability, reduced STAT3 and NFKB activity, and induced signs of apoptosis in 12Z cells. Furthermore, niclosamide inhibited cell viability that was stimulated by factors from macrophages, indicating that niclosamide was able to disrupt the ability of 12Z cells to respond to the secretions of the macrophages (summarized in Table 1 ). Key support to our hypothesis that niclosamide acts via modulation of the proinflammatory environment surrounding endometriotic lesions in vivo. It has been reported that peritoneal macrophages induce the inflammatory microenvironment and promote the establishment and growth of endometriotic lesions [14, 15, 46] . These macrophages derive from circulating monocytes that migrate into the peritoneal cavity where they differentiate and become polarized by cytokine/chemokine stimulation [16, 47] , whereas there are resident macrophages in the peritoneum. The macrophages secrete cytokines, which further exacerbate local inflammation. Elevated levels of ANG [48, 49] , ANGPT2 [50, 51] , BDNF [52] [53] [54] [55] , CCL2 [56] [57] [58] , CCL5 [56, 59] , CXCL10 [60] , CXCL12 [61] , IL10 [62, 63] , and MDK [64] have been reported in the endometriotic lesions, peritoneal fluid, and/or serum of women with endometriosis. Specifically, endometriotic cells and macrophages in the peritoneum are the primary sources of CCL2, aka monocyte chemoattractant protein-1, MCP-1, and CCL5, aka regulated on activation, normal T-cell expression and secreted, RANTES [59, [65] [66] [67] . CCL5 contributes to monocyte chemoattractant activity [65] . A macrophage-derived cytokine, IL-1β, can lead to CCL5 production and monocyte chemotaxis, as well as secretion of CCL5 by endometriotic lesions can further provide a mechanism for peritoneal leukocyte recruitment [67, 68] . Stem cell trafficking and role of CXCL12, aka stromal cell-derived factor-1, SDF-1, have been continuously demonstrated in the establishment, growth, and dissemination of endometriosis from Dr Hugh Taylor's group: CXCL12 via its ligand receptor CXCR4 promotes the invasion and engraftment of stem cells at the endometriotic lesions in the peritoneum [69, 70] . Its chemoattractive function is enhanced by steroid hormones [71] . Furthermore, endometriosis-derived cells are detected in the circulation, circulating endometriosis-derived cells express CXCR4 and mesenchymal stem cell markers, and these circulating stem cells contribute to endometriosis and angiogenesis. In addition, elevated CXCL12-CXCR4 signaling operates this dissemination and progression of the disease, indicating that CXCL12-CXCR4 signaling could be a potential target for treatment of endometriosis [72, 73] . MDK, aka Midkine, is also reported to promote the formation of intraperitoneal adhesion [74] . The results of the present study showed secretion of CCL5, CXCL12, and MDK in 12Z cells that were highly stimulated by macrophage factors and inhibited by niclosamide, especially CXCL12 stimulated by M2 macrophages was strongly suppressed by niclosamide. These results suggest that niclosamide can target and reduce inflammatory cytokine and chemokine stimulation of 12Z cells induced by macrophage factors. In addition, niclosamide may be able to disrupt endometriotic stem cell functions via inhibiting CXCL12-CXCR4 signaling, although it was not directly examined in the present study. Supporting this hypothesis, niclosamide can target chemoresistant stem-like cancer cells [26, 35, 37, 75, 76] .
Mixtures of recruited resident and/or differentiated macrophages exist in the peritoneum of endometriosis patients. As it is hard to replicate the complexity of macrophages using in vitro cellline base culture system, different phenotypes of monocyte-derived macrophages were used for the present study. It is presently unknown whether niclosamide inhibits proinflammatory responses of all macrophage types equivalently, but our defined system does support our hypothesis that niclosamide can act in vivo by modulation of the inflammatory microenvironment. While 12Z cell viability was stimulated by culturing with CM from multiple types of macrophages (M0, M1, or M2), stimulation of specific cytokine/chemokine production was dependent on macrophage phenotype. CCL5, CCL21, CXCL10, CXCL12, IL22, and MDK were stimulated by CM from both M1 and M2 macrophages. However, ANG, ANGPT2, BDNF, CCL2, CST3, IL10, and IL11 were only increased by M2 CM. M1 macrophages, classically activated by LPS and IFNγ , produce proinflammatory cytokines and initiate an immune response, whereas M2 macrophages are alternatively activated by IL4 and IL13, and are involved in promotion of tissue remodeling and tumor progression [77] . ANG, aka angiogenin [78] , ANGPT2, aka angiopoietin-2 [79] , and BDNF, aka brain derived neurotrophic factor [80] , are involved in stimulating angiogenesis. ANG activates capillary endothelial cells [78] . ANGPT2 is one of the key regulators of vascular quiescence facilitating angiogenesis with VEGF [81, 82] . BDNF is a family member of neurotrophins, and has been recognized as a regulator in the formation and maintenance of chronic pain in various chronic disorders [83] [84] [85] including endometriosis [52, 86] . Increased production of BDNF and NT-3 by estrogen stimulates neurite outgrowth from dorsal root ganglia, resulting in increased neuroangiogenesis [87] . BDNF polymorphism might contribute to the increased susceptibility to the advanced endometriosis and endometriosis-related infertility [88] . While ANG and BDNF did not directly increase 12Z cell viability, these angiogenic/neoangiogenic factors were stimulated by M2 macrophages. Thus, the results of the present study suggest that different types of macrophages can affect 12Z cells and are further involved in advanced progression of endometriosis and/or endometriosis-associated pain. Interestingly, niclosamide inhibits the elevated cytokines and chemokines in 12Z cells stimulated by different types of macrophages.
Collectively, the results of the present study indicate that 12Z cells were stimulated to secrete cytokines and chemokines by the factors from macrophages to probably further develop inflammatory microenvironment. Niclosamide could be an effective therapeutic drug for endometriosis inhibiting inflammatory mechanisms via STAT3 and/or NFKB signaling, suggesting that niclosamide is able to improve inflammatory microenvironment in the peritoneal cavity. The findings reported in the present study were cell line-based assays that have generated new hypotheses of pathways to target for improved endometriosis treatment. The effects of niclosamide on inflammation and its mechanisms using primary human samples are currently under investigation.
Supplementary data
Supplementary data are available at BIOLRE online. Table S1 . Primers for QPCR. Supplementary Figure S1 . Confirmation of macrophage activation. Relative mRNA expression levels of TNF, CD80, and IL10 were analyzed in M0, M1, and M2 macrophages. Supplementary Figure S2 . Conditioned media collected from 12Z cells primed with growth media (GM), M0, M1, or M2 conditioned media with/without niclosamide (1 μM) were analyzed for proteasome profiles of cytokine and chemokine. Secreted cytokines and chemokines were detected using chemiluminescent reagents and developed to autoradiography film. Selected factors for further analysis were marked with/as rectangular numbered 1 to 13. Supplementary Figure S3 . Confirmation of siRNA knockdown in 12Z cells. Western blots showing protein levels in cell lysate.
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